Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hamel

Showing results (311-320 of 323) with videos related to

Pageof 33
Sort By:
American Journal of Medical Genetics. Part A|February 27, 2010
Recurrent deletion of ZNF630 at Xp11.23 is not associated with mental retardationDorien Lugtenberg, Luiz Zangrande-Vieira, Maria Kirchhoff, et al.
Lancet (London, England)|May 10, 2026
Impact of introducing RTS,S/AS01<sub>E</sub> malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programmeVictor Mwapasa, Kwaku Poku Asante, Paul Milligan, et al.
Human Mutation|January 16, 2007
Mutation frequencies of X-linked mental retardation genes in families from the EuroMRX consortiumArjan P M de Brouwer, Helger G Yntema, Tjitske Kleefstra, et al.
Vaccine|November 12, 2019
Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan AfricaLucas Otieno, Yolanda Guerra Mendoza, Samuel Adjei, et al.
The Lancet. Infectious Diseases|September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialMichael T White, Robert Verity, Jamie T Griffin, et al.
Human Vaccines & Immunotherapeutics|April 24, 2019
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan AfricaYolanda Guerra Mendoza, Elodie Garric, Amanda Leach, et al.
Global Health Action|November 8, 2014
Cause-specific childhood mortality in Africa and Asia: evidence from INDEPTH health and demographic surveillance system sitesP Kim Streatfield, Wasif A Khan, Abbas Bhuiya, et al.
Nature Genetics|June 16, 2009
Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune responseGillian I Rice, Jacquelyn Bond, Aruna Asipu, et al.
Global Health Action|November 8, 2014
Malaria mortality in Africa and Asia: evidence from INDEPTH health and demographic surveillance system sitesP Kim Streatfield, Wasif A Khan, Abbas Bhuiya, et al.
The New England Journal of Medicine|October 22, 2015
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria VaccineD E Neafsey, M Juraska, T Bedford, et al.
Pageof 33

Showing results (311-320 of 323) with videos related to

Sort By:
Pageof 33
American Journal of Medical Genetics. Part A|February 27, 2010
Recurrent deletion of ZNF630 at Xp11.23 is not associated with mental retardationDorien Lugtenberg, Luiz Zangrande-Vieira, Maria Kirchhoff, et al.
Lancet (London, England)|May 10, 2026
Impact of introducing RTS,S/AS01<sub>E</sub> malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programmeVictor Mwapasa, Kwaku Poku Asante, Paul Milligan, et al.
Human Mutation|January 16, 2007
Mutation frequencies of X-linked mental retardation genes in families from the EuroMRX consortiumArjan P M de Brouwer, Helger G Yntema, Tjitske Kleefstra, et al.
Vaccine|November 12, 2019
Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan AfricaLucas Otieno, Yolanda Guerra Mendoza, Samuel Adjei, et al.
The Lancet. Infectious Diseases|September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialMichael T White, Robert Verity, Jamie T Griffin, et al.
Human Vaccines & Immunotherapeutics|April 24, 2019
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan AfricaYolanda Guerra Mendoza, Elodie Garric, Amanda Leach, et al.
Global Health Action|November 8, 2014
Cause-specific childhood mortality in Africa and Asia: evidence from INDEPTH health and demographic surveillance system sitesP Kim Streatfield, Wasif A Khan, Abbas Bhuiya, et al.
Nature Genetics|June 16, 2009
Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune responseGillian I Rice, Jacquelyn Bond, Aruna Asipu, et al.
Global Health Action|November 8, 2014
Malaria mortality in Africa and Asia: evidence from INDEPTH health and demographic surveillance system sitesP Kim Streatfield, Wasif A Khan, Abbas Bhuiya, et al.
The New England Journal of Medicine|October 22, 2015
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria VaccineD E Neafsey, M Juraska, T Bedford, et al.
Pageof 33